ストックスクリーナーアプリを入手
900.05
1.30%
10.41
前日終値:
$889.64
開ける：
$888.01
24時間の取引高:
341.81K
Relative Volume:
0.97
時価総額：
$55.17B
収益：
$3.06B
当期純損益:
$1.28B
株価収益率:
45.75
EPS:
19.6719
ネットキャッシュフロー:
$447.35M
1週間 パフォーマンス:
+8.27%
1か月 パフォーマンス:
+13.08%
6か月 パフォーマンス:
+60.67%
1年 パフォーマンス:
+51.73%
1日の値動き範囲:
$885.81
$907.47
1週間の範囲:
$831.26
$907.47
52週間の値動き範囲:
$510.06
$907.47
Argen X Se Adr Stock (ARGX) Company Profile
ARGX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ARGX
Argen X Se Adr
|
901.55 | 53.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
433.27 | 106.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
685.94 | 68.81B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
455.28 | 58.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
374.16 | 36.43B | 4.56B | -176.77M | 225.30M | -1.7177 |
Argen X Se Adr Stock (ARGX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-09-15 | 再開されました | Truist | Buy |
| 2025-09-11 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2025-08-25 | 開始されました | RBC Capital Mkts | Outperform |
| 2025-07-08 | アップグレード | Deutsche Bank | Hold → Buy |
| 2025-07-03 | 再開されました | Morgan Stanley | Overweight |
| 2025-05-13 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2025-03-17 | アップグレード | Bernstein | Mkt Perform → Outperform |
| 2025-03-12 | アップグレード | Deutsche Bank | Sell → Hold |
| 2025-01-17 | ダウングレード | Deutsche Bank | Hold → Sell |
| 2024-11-12 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2024-11-05 | アップグレード | Scotiabank | Sector Perform → Sector Outperform |
| 2024-11-01 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2024-11-01 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2024-10-10 | 再開されました | Raymond James | Strong Buy |
| 2024-10-04 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2024-08-06 | アップグレード | Barclays | Equal Weight → Overweight |
| 2024-07-25 | アップグレード | Deutsche Bank | Hold → Buy |
| 2024-07-23 | アップグレード | Oppenheimer | Perform → Outperform |
| 2024-02-15 | 開始されました | Wolfe Research | Peer Perform |
| 2023-12-20 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2023-12-20 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2023-07-31 | 開始されました | Scotiabank | Sector Perform |
| 2023-07-24 | ダウングレード | UBS | Buy → Neutral |
| 2023-07-17 | 再開されました | Evercore ISI | Outperform |
| 2023-06-15 | 開始されました | Societe Generale | Sell |
| 2023-05-31 | 開始されました | UBS | Buy |
| 2023-04-25 | 開始されました | Citigroup | Buy |
| 2023-03-14 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2022-12-07 | 開始されました | William Blair | Outperform |
| 2022-10-12 | 開始されました | Oppenheimer | Perform |
| 2022-07-29 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2022-06-28 | 再開されました | Stifel | Buy |
| 2022-05-03 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2021-12-08 | 開始されました | Wells Fargo | Overweight |
| 2021-11-29 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2021-10-29 | アップグレード | Guggenheim | Neutral → Buy |
| 2021-10-28 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2021-10-07 | 開始されました | Jefferies | Buy |
| 2021-09-23 | アップグレード | Redburn | Neutral → Buy |
| 2021-09-07 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-07-23 | 開始されました | Deutsche Bank | Hold |
| 2021-07-19 | 再開されました | Wolfe Research | Outperform |
| 2021-06-18 | 開始されました | UBS | Buy |
| 2021-06-04 | 再開されました | Robert W. Baird | Outperform |
| 2021-05-10 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2021-04-23 | 開始されました | Redburn | Neutral |
| 2021-03-05 | 繰り返されました | H.C. Wainwright | Neutral |
| 2021-02-02 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2021-01-04 | ダウングレード | Guggenheim | Buy → Neutral |
| 2020-08-25 | 開始されました | Raymond James | Outperform |
| 2020-08-19 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2020-07-29 | 開始されました | H.C. Wainwright | Neutral |
| 2020-02-10 | 開始されました | BofA/Merrill | Buy |
| 2019-11-05 | 開始されました | Credit Suisse | Neutral |
| 2019-10-31 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2019-10-22 | 開始されました | JP Morgan | Overweight |
| 2019-09-27 | 開始されました | Wells Fargo | Market Perform |
| 2019-09-16 | 再開されました | Cowen | Outperform |
| 2019-06-28 | 開始されました | Robert W. Baird | Outperform |
| 2019-01-18 | 再開されました | SunTrust | Buy |
| 2019-01-04 | 開始されました | Morgan Stanley | Overweight |
| 2018-12-17 | 開始されました | Goldman | Buy |
| 2018-12-14 | 開始されました | Wolfe Research | Outperform |
| 2018-06-29 | 開始されました | Nomura | Buy |
| 2018-04-09 | 開始されました | SunTrust | Buy |
| 2018-01-29 | 繰り返されました | JMP Securities | Mkt Outperform |
すべてを表示
Argen X Se Adr (ARGX) 最新ニュース
Argenx NV ADR stock hits all-time high of 855.68 USD - Investing.com Nigeria
Denali Therapeutics Announces Board and Executive Leadership Updates - GlobeNewswire Inc.
Janus Henderson Global Life Sciences Fund Q3 2025 Commentary - Seeking Alpha
argenx Announces VYVGART SC Prefilled Syringe for Self-Injection in Chronic Inflammatory Demyelinating Polyneuropathy Authorized for Sale by Health Canada - Barchart.com
Piper Sandler raises argenx stock price target to $930 on strong Vyvgart sales By Investing.com - Investing.com South Africa
Piper Sandler raises argenx stock price target to $930 on strong Vyvgart sales - Investing.com
Vyvgart Fuels Strong Growth for Argenx and Supports Developing Pipeline - Morningstar
argenx SE stock price target raised to $1,146 from $800 at TD Cowen - Investing.com Philippines
argenx ADR earnings beat by $0.74, revenue topped estimates - Investing.com Canada
Argenx rises after Q3 earnings beat on strong sales growth By Investing.com - Investing.com South Africa
Argenx rises after Q3 earnings beat on strong sales growth - Investing.com India
argenx Reports Third Quarter 2025 Financial Results and Provides Business Update - Sahm
Baron Health Care Fund Q3 2025 Top Contributors And Detractors - Seeking Alpha
Milei's Landslide Election Victory Sends Argentina Stocks Soaring: 5 Names To Watch - Sahm
argenx to Report Third Quarter 2025 Financial Results and Business Update on October 30, 2025 - Sahm
ETFs Investing in argenx SE Sponsored ADR Stocks - TradingView
Argx stock hits all-time high at 821.97 USD By Investing.com - Investing.com Philippines
Argx stock hits all-time high at 821.97 USD - Investing.com India
TD Cowen Remains a Buy on Argenx Se (ARGX) - The Globe and Mail
argenx stock price target maintained at $800 by TD Cowen on strong Vyvgart uptake - Investing.com
Argenx Se (ARGX) Gets a Buy from Evercore ISI - The Globe and Mail
How Do Investors Really Feel About argenx SE? - Sahm
RBC Capital Remains a Buy on Argenx Se (ARGX) - The Globe and Mail
Argenx SE Sponsored ADR (ARGX) Stock Forecast & Price Targets: Today, Tomorrow, Next Week - Traders Union
Stocks Showing Improved Relative Strength: Zai Lab ADR - inkl
Argenx NV stock hits all-time high at 803.95 USD By Investing.com - Investing.com South Africa
Argenx NV stock hits all-time high at 803.95 USD - Investing.com
Neuromuscular Disease Therapeutics Market to Reach US$ 45.62 Billion by 2033 as Gene Therapies and RNA-based Treatments Redefine Patient Outcomes - 富途牛牛
Argenx SE Calls Extraordinary Shareholder Meeting for November 2025 - The Globe and Mail
Structure Therap ADR Earns Relative Strength Rating Upgrade - inkl
Goldman Sachs Sticks to Its Buy Rating for Argenx Se (ARGX) - The Globe and Mail
Argenx stock hits all-time high at 781.12 USD By Investing.com - Investing.com Australia
Argenx stock hits all-time high at 781.12 USD - Investing.com
Argenx Se (ARGX) Receives a Buy from RBC Capital - The Globe and Mail
Here's How Much $100 Invested In argenx 5 Years Ago Would Be Worth Today - Sahm
Barclays Sticks to Its Buy Rating for Lonza Group Ltd (LONN) - The Globe and Mail
Price Over Earnings Overview: argenx - Sahm
Leerink Partners Keeps Their Buy Rating on Viridian Therapeutics (VRDN) - The Globe and Mail
Barclays Sticks to Their Hold Rating for Roche Holding AG (RHHVF) - The Globe and Mail
Argenx Se (ARGX) Receives a Rating Update from a Top Analyst - The Globe and Mail
Oppenheimer reaffirms Outperform rating on argenx stock after positive data - Investing.com
Truist Securities reiterates Buy rating on argenx stock with $918 target - Investing.com
$1000 Invested In argenx 5 Years Ago Would Be Worth This Much Today - Sahm
Analysts Offer Insights on Healthcare Companies: Abivax SA Sponsored ADR (ABVX), KalVista Pharmaceuticals (KALV) and Argenx Se (ARGX) - The Globe and Mail
Truist Securities assumes coverage on argenx stock with Buy rating - Investing.com
Deutsche Bank downgrades Argenx to “hold” after 40% rally, €655 PT intact - Investing.com
14 Newly Overvalued Stocks for the Week - Morningstar
Why Dianthus Therapeutics, Up 47% In Four Weeks, Just Surged Again - Investor's Business Daily
Argenx stock hits all-time high at 716.89 USD - Investing.com
Stocks Showing Improving Market Leadership: argenx ADR Earns 84 RS Rating - MSN
Argenx Stock Hits Record High After Reporting 664% Earnings Surge; This Rating Upgraded - Investor's Business Daily
Argen X Se Adr (ARGX) 財務データ
収益
当期純利益
現金流量
EPS
0.85%
0.10%
大文字化:
|
ボリューム (24 時間):